Renaissance Technologies LLC Has $624,000 Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Renaissance Technologies LLC lifted its position in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 698.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 367,300 shares of the company's stock after buying an additional 321,300 shares during the quarter. Renaissance Technologies LLC owned about 0.90% of Vigil Neuroscience worth $624,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Blair William & Co. IL acquired a new stake in Vigil Neuroscience in the fourth quarter valued at approximately $551,000. abrdn plc lifted its stake in shares of Vigil Neuroscience by 124.9% in the 4th quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after purchasing an additional 293,461 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock valued at $769,000 after purchasing an additional 66,712 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Analyst Ratings Changes

VIGL has been the topic of several recent research reports. HC Wainwright cut their target price on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Friday, March 14th. Guggenheim reissued a "buy" rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Wedbush reduced their target price on Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating for the company in a report on Friday, March 14th. Finally, William Blair upgraded Vigil Neuroscience to a "strong-buy" rating in a report on Thursday, April 24th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Vigil Neuroscience currently has a consensus rating of "Buy" and a consensus target price of $16.25.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL opened at $2.75 on Friday. The stock's 50-day moving average is $1.92 and its 200-day moving average is $2.37. The company has a market cap of $135.09 million, a P/E ratio of -1.33 and a beta of 1.94. Vigil Neuroscience, Inc. has a 52-week low of $1.31 and a 52-week high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08). As a group, equities analysts predict that Vigil Neuroscience, Inc. will post -2.07 EPS for the current year.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.